Partnership to Combine AbbVie's Oncology Expertise with EvolveImmune's Proprietary EVOLVE T-Cell Engager Platform to Develop Novel Multispecific Therapeutic Antibodies for Cancer NORTH CHICAGO, Ill. and BRANFORD, Conn., Oct. 31, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) and EvolveImmune Therapeutics, an immuno-oncology company developing next-generation biotherapeutics to overcome the therapeutic challenges of cancer cell resistance to current immunotherapies, today announced a collaboration and option-to-li ...

It's hard to beat the power of dividend-paying stocks. They have outperformed non-payers significantly. If you don't have many dividend-paying stocks in your portfolio, you might want to rethink your asset allocation because dividend payers can be surprisingly powerful long-term performers. For starters, a company generally needs to grow enough to have relatively reliable income, giving management the confidence with which to initiate -- and then maintain -- a dividend payment to shareholders. Such companie ...

Since I last checked on pharmaceutical company AbbVie Inc. (NYSE: ABBV ) in August, its share price hasn't gone anywhere. But the release of its third quarter (Q3 2024) results shows investors are happy Manika is a macroeconomist with over 20 years of experience in industries including investment management, stock broking, investment banking. She also runs the profile Long Term Tips [LTT], which focuses on the generational opportunity in the green economy. Her investing group, Green Growth Giants , takes th ...

AbbVie Inc. (NYSE:ABBV) Q3 2024 Earnings Conference Call October 30, 2024 9:00 AM ET Company Participants Liz Shea - Senior Vice President, Investor Relations Robert A. Michael - C hief Executive Officer Jeffrey R. Stewart - Executive Vice President, Chief Commercial Officer Roopal Thakkar - Executive Vice President, Research & Development, Chief Scientific Officer Scott T. Reents - Executive Vice President, Chief Financial Officer Carrie Strom - Senior Vice President, AbbVie and President, Global Allergan ...

AbbVie Inc. (ABBV) reported adjusted earnings of $3.00 per share for the third quarter of 2024, beating the Zacks Consensus Estimate of $2.92. The reported earnings also exceeded the company's guidance of $2.88-$2.92 issued earlier this month. Earnings increased 1.7% year over year. ABBV's revenues of $14.46 billion also beat the Zacks Consensus Estimate of $14.28 billion. Sales rose 3.8% year over year on a reported basis and 4.9% on an operational basis. Revenues in third quarter were driven by robust sal ...

For the quarter ended September 2024, AbbVie (ABBV) reported revenue of $14.46 billion, up 3.8% over the same period last year. EPS came in at $3.00, compared to $2.95 in the year-ago quarter.The reported revenue represents a surprise of +1.29% over the Zacks Consensus Estimate of $14.28 billion. With the consensus EPS estimate being $2.92, the EPS surprise was +2.74%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their ...

AbbVie (ABBV) came out with quarterly earnings of $3 per share, beating the Zacks Consensus Estimate of $2.92 per share. This compares to earnings of $2.95 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 2.74%. A quarter ago, it was expected that this drugmaker would post earnings of $2.57 per share when it actually produced earnings of $2.65, delivering a surprise of 3.11%. Over the last four quarters, the company has surpass ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________________ FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 3, 2024 ABBVIE INC. (Exact name of registrant as specified in its charter) Delaware 001-35565 (State or other Jurisdiction (Commission File Number) of Incorporation) _____________________________________________________ 1 North Wauke ...

Reports Third-Quarter Diluted EPS of $0.88 on a GAAP Basis, a Decrease of 12.0 Percent; Adjusted Diluted EPS of $3.00, an Increase of 1.7 Percent; These Results Include an Unfavorable Impact of $0.04 Per Share Related to Acquired IPR&D and Milestones Expense  Delivers Third-Quarter Net Revenues of $14.460 Billion, an Increase of 3.8 Percent on a Reported Basis or 4.9 Percent on an Operational Basis  Third-Quarter Global Net Revenues from the Immunology Portfolio Were $7.046 Billion, an Increase of 3.9 Per ...

These 3 dividend growth stocks have crushed the market and show no signs of slowing down.The power of dividend growth investing lies in one simple truth: Companies that consistently raise their dividends have historically outperformed the broader market since 1900. These elite businesses combine robust revenue growth, strong fundamentals, and shareholder-friendly management teams.The greatest dividend growth stories share common traits: durable competitive advantages, reasonable payout ratios, and proven re ...